Samsung Biologics Secures KRW 149.1 Billion in CMO Add-Ons as Union Plans Independence Vote
Samsung Biologics (207940.KS) has disclosed two contract manufacturing (CMO) expansions totaling KRW 149.1 billion (approx. USD 99.4 million) via DART filings in June 2026, adding to a cumulative backlog now approaching USD 10.4 billion. The wins arrive as the company's labor union prepares a vote on whether to break away from Samsung Group's conglomerate-wide federation — a decision that analysts say could complicate ongoing wage negotiations and production stability heading into the second half.
Part A — The Contracts
European Pharma Expansion (June 9)
Samsung Biologics raised an existing European pharmaceutical contract by KRW 50.7 billion, lifting the total value of that agreement from KRW 349.9 billion to KRW 400.7 billion. The counterparty's identity is subject to a business-confidentiality clause and is scheduled for public disclosure in 2031.
U.S. Pharma Expansion (June 17)
A second expansion — with a U.S.-based pharmaceutical company — added KRW 98.3 billion (USD 68.56 million) to an agreement first disclosed in April 2025 at KRW 737.3 billion. The contract is now valued at KRW 835.6 billion. This counterparty's identity will be revealed in 2032.
Running Backlog
Including both expansions, Samsung Biologics' cumulative contracted revenue (on a minimum-purchase basis, as of Q1 2026 end) rises from approximately USD 10.272 billion to roughly USD 10.375 billion (KRW ~15.56 trillion), using an exchange rate of KRW 1,500 per U.S. dollar applied by the company.
The disclosures come as Samsung Biologics showcases its capacity at BIO International Convention 2026 (San Diego, June 22–25), where it occupies a 140-square-metre booth at the centre of the convention floor — its fourteenth consecutive year with a standalone exhibit. The company completed the acquisition of a Rockville, Maryland campus (from GlaxoSmithKline) in Q1 2026 for approximately USD 353 million, lifting total production capacity to 845,000 litres. Its fifth plant at Songdo, Incheon, is currently in the ramp-up phase.
Part B — Labor Standoff Clouds the Outlook
Despite the contract wins, Samsung Biologics faces a protracted wage dispute that is drawing scrutiny from investors and sell-side analysts.
Timeline: - May 1–5, 2026 — The union staged the company's first-ever five-day full walkout in its 15-year history. Management estimated production disruption at roughly KRW 150 billion (~25% of Q1 2026 operating profit). Disrupted lines included certain oncology and HIV treatment manufacturing steps. - May onward — Following the expiry of government-led mediation in May, both sides shifted to direct talks. The union pivoted to a work-to-rule campaign — refusing overtime and holiday assignments — which remains in effect. - June 24–28 — The union is set to hold an internal vote on exiting the Samsung Group enterprise union federation, citing difficulty in coordinating across multiple subsidiaries with differing interests. An affirmative vote would give the union sole bargaining authority at Samsung Biologics.
The Wage Gap
The union is seeking an average 14.3% base-pay raise plus a KRW 3.5 million flat bonus per employee. Management's last public offer stands at a 6.2% increase. Bonuses remain a separate sticking point: the union requests 20% of operating profit; management has proposed 10%.
Workforce and Financial Context
Samsung Biologics employs approximately 5,455 workers. Samsung Securities analyst Seo Geun-hee projects that total labour costs could reach KRW 293.1 billion this year — 75% above prior estimates — and has cut the 12-month target price from KRW 2,100,000 to KRW 1,800,000, citing reduced operating-profit forecasts. KB Securities' Shin Ji-hoon maintains a Buy rating with a KRW 1,900,000 target, viewing the medium-term growth case as intact.
The company's 2026 revenue guidance stands at a +15–20% increase over 2025's KRW 4.57 trillion (implying KRW 5.2–5.5 trillion). An escalation of labour disruptions, or a prolonged independence process at the union level, could weigh on production throughput at the Songdo campus during a period when Plant 5 is critical to meeting contract obligations.
BIOSECURE Act Tailwind
The U.S. Biosecure Act, which targets Chinese CDMO firms including WuXi Biologics, continues to redirect global pharmaceutical sourcing toward non-Chinese providers. Analysts broadly regard Samsung Biologics as a primary beneficiary of this structural supply-chain realignment, a dynamic that lends longer-term credibility to the contract-expansion trend disclosed this month.
Sources: Samsung Biologics DART filings (June 9, June 17, 2026); Chosunbiz (June 22, 2026); Korea Herald; The Elec
